Vernalis shares spike on U.S. reformulation deal; Mobius gets an FDA OK for glaucoma treatment;

@FierceBiotech: U.S.-based EMC to found Russian cloud-computing, 'Big Data' hub in the Skolkovo Foundation's Innovation Hub. Story | Follow @FierceBiotech

@JohnCFierce: This mouse study on Alzheimer's and bexarotene grabbing lots of headlines. Scientists sound level headed about it. Article | Follow @JohnCFierce

@FierceMedDev: Deal talk: Roche, Glencore spark hope of European M&A revival. Item via @Reuters | Follow @FierceMedDev

@MarkHFierce: A patient's genetics could possibly guide TB treatment, it turns out. Another win for gene sequencing? More | Follow @MarkHFierce

> The one-time British biotech bellwether Vernalis ($VER.L) has struck a deal with Tris Pharma in the U.S. to develop slow-release cold and cough meds for the American market. A number of meds could be reformulated with its technology, says Vernalis, which saw its shares spike 28% on the news. Story

> Mobius Therapeutics received an FDA OK for Mitosol in glaucoma surgery. Release

> Silence Therapeutics has promoted Chief Business Officer Tony Sedgwick to the CEO post. Release

> Nodality and UCB Pharma announced a strategic collaboration using Nodality's Single Cell Network Profiling tech in the development of several UCB compounds. Release

Pharma News

@FiercePharma: Will mid-2012 be the turning point for European pharma stocks? Maybe so, WSJ says. Item | Follow @FiercePharma

> WellPoint to drop branded Lipitor from its formulary. News

> Merck says Victrelis can interfere with HIV meds. Article

> LEO Pharma slapped with sales-rep overtime suit. Story

> GSK, Takeda say nay to in-house diagnostics units. More

And Finally... Scientists say curcumin, an active component of the Indian curry spice turmeric, may help slow tumor growth in castration-resistant prostate cancer patients on androgen deprivation therapy. Release

Suggested Articles

A new clinical hold is the latest setback for Solid Biosciences and the development of its gene therapy for Duchenne muscular dystrophy.

VBI's Sci-B-Vac protected twice as many people than GSK's Engerix-B did after the second dose.

The notice comes weeks after Amgen revealed it was retreating from its East Coast neuroscience operations.